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Ideally, biological markers of an individual breast cancer will
provide information about (1) prognosis for the patient, (2) the
best first-line therapy, (3) response to that therapy, (4) early
relapse, (5) targets for new therapies and (6) the biology of breast
cancer. No single marker could provide all this information and, in
any case, the heterogeneous nature of individual breast cancers
makes it unlikely that a single marker could reflect the overall
potential of the tumour. This suggests that we should look for
groups of markers but so many possible markers have been
described over the past 20 years that selection of the best combina-
tion of markers will be difficult.
The best established marker in breast cancer is the oestrogen
receptor (ER). Its role in prognosis and in predicting response to
both adjuvant therapy and therapy for advanced disease has been
well described (Elledge and Osborne, 1997; Leake, 1997; EBTG,
1998). Successful quality assurance (QA) exists for the biochem-
ical assay (Romain et al, 1995) and a similar QA scheme is being
established for the immunohistochemistry (Barnes et al, 1998) of
ER. Largely because of this solid background, a recent study in the
UK by Mander et al (1998) showed that only 12.5% of breast
cancer units ‘do not believe ER status to be important in the
management of primary breast cancer’ and ER is routinely
measured in over 84% of breast disease specialist centres. The
authors conclude that failure to measure informative biological
markers can ‘contribute to differences in outcome between units’.
Thus, we have an informative marker, which is both relatively
cheap and easy to measure, has a well established QA scheme and
is very well defined from studies on large numbers of patients
(Romain et al, 1995). However, it has taken 25 years to get routine
ER measurement established. If there is a valid case for the use of
other markers, as we believe, then we hope that it will not take so
long for them to reach routine use!
There is a wide range of potential markers, including oncogene
products such as erbB-2, anti-oncogene products such as p53,
markers of apoptosis/entry into S phase such as bcl-2, markers of
cell growth such as Ki-67 and markers of invasion/early relapse
such as the urokinase family, whose potential roles have been
regularly reported (see Dowsett (1998) for review and Schmitt et
al (1997) for details of the potential of the urokinase family). The
problem is to select those combinations of biological markers
which provide most information for appropriate sub-groups of
patients. However, these combinations of markers will only be
established in sound manner if each appropriate clinical trial
includes a biomarkers component. All protocols proposed through
the EORTC are now checked for the presence or possible insertion
of such biological end points. Any biomarker study must, of
course, obey established rules on tissue handling, assay procedures
and data analysis. Appropriate external QA must be included for
all multi-centre assays. Hayes et al (1996) have provided one
framework to evaluate the clinical utility of such markers.
New technologies such as reverse transcription polymerase
chain reaction on fine-needle aspirates, or DNA microarrays make
it much more realistic to work on the small quantities of tissue now
available. If the result of the application to patient management of
specific packages of biomarkers is to improve therapy selection,
reduce overtreatment and increase the quality of life, then such an
approach will be a cost-effective development.
Is there any evidence that biological markers could act in such a
useful manner? Stal et al (1995) carried out a retrospective study
of two biomarkers (erbB-2 and S Phase Fraction) in patients who
had been randomized to receive either radiotherapy or CMF.
Patients with high S Phase but low erbB-2 responded well to
chemotherapy and had a much longer disease-free interval than
those treated with radiotherapy, whereas patients with high erbB-2
but low S Phase did much better after radiotherapy than after
chemotherapy. These results suggest that biological markers can
make a difference. Several other retrospective studies will be
published shortly. The outcome of prospective studies is eagerly
awaited!
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